US Stock MarketDetailed Quotes
CRDL Cardiol Therapeutics
- 2.0900
- +0.0900+4.50%
Close Jul 19 16:00 ET
- 2.1800
- +0.0900+4.31%
Post 17:41 ET
145.03MMarket Cap-6093P/E (TTM)
2.1198High1.9906Low172.25KVolume2.0300Open2.0000Pre Close357.70KTurnover0.26%Turnover RatioLossP/E (Static)69.39MShares3.120052wk High9.91P/B138.21MFloat Cap0.661052wk Low--Dividend TTM66.13MShs Float4.9600Historical High--Div YieldTTM6.46%Amplitude0.4500Historical Low2.0760Avg Price1Lot Size
Cardiol Therapeutics Stock Forum
Sign in to post a comment
$Cardiol Therapeutics(CRDL.US$
Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
Cardiol Therapeutics announced positive topline data from its Phase II MAvERIC-Pilot study, evaluating CardiolRxTM for treating recurrent pericarditis. The 8-week clinical data showed a significant reduction in pericarditis pain and inflammation. The study involved 27 patients, and 89% continued into the extension ph...
Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
Cardiol Therapeutics announced positive topline data from its Phase II MAvERIC-Pilot study, evaluating CardiolRxTM for treating recurrent pericarditis. The 8-week clinical data showed a significant reduction in pericarditis pain and inflammation. The study involved 27 patients, and 89% continued into the extension ph...
1
5
4
$Cardiol Therapeutics(CRDL.US$
NEWS
Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024
Cardiol Therapeutics presented its Phase II ARCHER trial at the World Congress on Acute Heart Failure 2024. The trial is evaluating CardiolRx™ in patients with acute myocarditis. The presentation included the trial design, rationale, and baseline data on the first 50 patients randomized. The ARCHER trial has exceeded 85% of target enrollment, with ...
NEWS
Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024
Cardiol Therapeutics presented its Phase II ARCHER trial at the World Congress on Acute Heart Failure 2024. The trial is evaluating CardiolRx™ in patients with acute myocarditis. The presentation included the trial design, rationale, and baseline data on the first 50 patients randomized. The ARCHER trial has exceeded 85% of target enrollment, with ...
1
1
$Cardiol Therapeutics(CRDL.US$ Cardiol is well positioned to achieve significant milestones in the MAvERIC, ARCHER, and CRD-38 programs during 2024. There is supposedly a data release coming before end of 1H! NFA just thinking outloud!![]()
2
2
$Cardiol Therapeutics(CRDL.US$ Cardiol Therapeutics Completes Patient Enrollment in Its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis![]()
1
9
$Cardiol Therapeutics(CRDL.US$ Its trying to get back to the HOD that happened earlier when i posted the FDA approval PR![]()
1
$Cardiol Therapeutics(CRDL.US$Moomoo 24/7· 2 mins ago
Cardiol Therapeutics Says FDA Granted Orphan Drug Designation For Its Lead Drug Candidate For Treatment Of Pericarditis![]()
Cardiol Therapeutics Says FDA Granted Orphan Drug Designation For Its Lead Drug Candidate For Treatment Of Pericarditis
$Cardiol Therapeutics(CRDL.US$ Cardiol Therapeutics Regains Compliance With All Applicable Listing Standards of The Nasdaq Capital Market![]()
$Cardiol Therapeutics(CRDL.US$ Cardiol Therapeutics Exceeds 50% Enrollment In Phase II ARCHER Trial In Acute Myocarditis![]()
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Anil Datta : Price dropped and 10 time stocks traded any guess what happened?
Jaguar8OP Anil Datta: Always expect shorts to attack
Anil Datta Jaguar8OP: When shorts attack price normally goes down?
Jaguar8OP Anil Datta: Definitely.
Anil Datta Jaguar8OP: Good morning any other stocks you are fallowing Can you share please